Barclays PLC Reduces Holdings in Quanterix Co. (NASDAQ:QTRX)

Barclays PLC lessened its position in shares of Quanterix Co. (NASDAQ:QTRX) by 11.4% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 129,644 shares of the company’s stock after selling 16,604 shares during the quarter. Barclays PLC owned about 0.34% of Quanterix worth $1,378,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in QTRX. JPMorgan Chase & Co. raised its position in Quanterix by 23.9% in the fourth quarter. JPMorgan Chase & Co. now owns 270,054 shares of the company’s stock valued at $2,871,000 after purchasing an additional 52,097 shares during the period. Graypoint LLC purchased a new stake in Quanterix in the 4th quarter valued at about $691,000. Envestnet Asset Management Inc. raised its holdings in Quanterix by 22.5% in the 4th quarter. Envestnet Asset Management Inc. now owns 342,264 shares of the company’s stock valued at $3,638,000 after buying an additional 62,757 shares during the period. Bank of New York Mellon Corp lifted its position in Quanterix by 1.8% in the fourth quarter. Bank of New York Mellon Corp now owns 108,186 shares of the company’s stock valued at $1,150,000 after buying an additional 1,963 shares during the last quarter. Finally, Vanguard Group Inc. boosted its stake in Quanterix by 0.9% during the fourth quarter. Vanguard Group Inc. now owns 2,217,225 shares of the company’s stock worth $23,569,000 after buying an additional 19,386 shares during the period. 86.48% of the stock is currently owned by institutional investors and hedge funds.

Quanterix Trading Up 4.2 %

Shares of NASDAQ QTRX opened at $6.01 on Friday. The stock has a market cap of $233.12 million, a P/E ratio of -5.67 and a beta of 1.12. The business’s fifty day simple moving average is $6.35 and its 200-day simple moving average is $9.32. Quanterix Co. has a 12-month low of $4.67 and a 12-month high of $19.18.

Quanterix (NASDAQ:QTRX) last announced its quarterly earnings data on Monday, March 17th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.27) by ($0.03). Quanterix had a negative net margin of 30.12% and a negative return on equity of 11.74%. The company had revenue of $35.16 million during the quarter, compared to analysts’ expectations of $34.93 million. On average, equities analysts forecast that Quanterix Co. will post -0.98 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on QTRX shares. Scotiabank restated an “outperform” rating on shares of Quanterix in a report on Tuesday, March 25th. Canaccord Genuity Group decreased their price target on Quanterix from $20.00 to $15.00 and set a “buy” rating on the stock in a research note on Tuesday, March 18th. Leerink Partners reaffirmed a “market perform” rating and issued a $8.00 price objective (down from $12.00) on shares of Quanterix in a research note on Wednesday. Finally, Leerink Partnrs lowered Quanterix from a “strong-buy” rating to a “hold” rating in a research note on Wednesday. Three analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $16.20.

Quanterix Company Profile

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.